Last reviewed · How we verify
Higher dose marketed paracetamol
At a glance
| Generic name | Higher dose marketed paracetamol |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults (PHASE1)
- A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations (PHASE1)
- At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Higher dose marketed paracetamol CI brief — competitive landscape report
- Higher dose marketed paracetamol updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI